Saturday 17 October 2026
Export ITRMF’s income statement to Excel — free account
Iterum Therapeutics PLC
ITRMF Healthcare Biotechnology
In the quarter to September 2025, revenue grew 110.8%, EPS grew 33.3% and free cash flow fell 179.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.00
0.00
NaN
Follow ITRMF
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Piotroski F-Score |
— | — | — | 2 | — | — | — | — | — |
P/S ratio |
— | 0.00 | 50.38 | 91.42 | — | — | — | — | — |
Altman Z-Score |
— | — | (2.47) | (26.27) | — | — | — | — | — |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | 2.90 | (1.37) | (63.33) | — | — | — | — | — |
P/Operating CF |
— | (0.22) | (1.84) | (2.84) | — | — | — | — | — |
Beneish M-Score |
— | — | (2.37) | 22.81 | — | — | — | — | — |
P/B ratio |
— | 0.11 | 0.61 | 0.00 | — | — | — | — | — |
Price to Tangible BV |
— | 0.11 | 0.61 | 0.00 | — | — | — | — | — |
EV/Sales |
— | 0.00 | (30.73) | 103.44 | — | — | — | — | — |
EV/EBITDA |
— | 0.00 | 0.35 | 0.00 | — | — | — | — | — |
EV/Operating CF |
— | 0.53 | 0.35 | (0.90) | — | — | — | — | — |
EV/FCF |
— | 0.52 | 0.35 | (0.90) | — | — | — | — | — |
Quick Ratio |
5.94 | 5.57 | 6.98 | 0.16 | 0.37 | 6.38 | 6.74 | 1.77 | 1.37 |
Current Ratio |
6.13 | 6.20 | 7.61 | 0.32 | 0.51 | 6.43 | 6.89 | 1.89 | 1.41 |
Net Debt/EBITDA |
1.86 | 1.33 | 0.93 | (0.08) | (0.68) | 3.97 | 1.93 | 0.29 | 0.24 |
Debt/Assets |
0.00% | 0.00% | 14.40% | 52.13% | 87.94% | 9.35% | 15.10% | 43.62% | 45.52% |
Debt/Equity |
0.00 | 0.00 | 0.20 | (0.51) | (0.57) | 0.17 | 0.36 | (1.79) | (4.97) |
Asset Turnover |
0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.84 | 1.04 | 0.98 | 0.79 | 1.05 | 0.17 | 0.42 | 1.03 | 1.08 |
Capex/Depreciation |
— | (12.49) | (0.18) | (0.05) | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 |
Interest Coverage |
— | (106.34) | — | (118.49) | (2.13) | (4.42) | (12.87) | (33.24) | (7.41) |
| (43.29%) | (94.61%) | (138.69%) | (454.48%) | 135.44% | 56,347.08% | (113.59%) | (355.35%) | 472.61% | |
| (36.55%) | (79.83%) | (106.56%) | (166.85%) | (177.67%) | (147.33%) | (56.12%) | (82.44%) | (69.93%) | |
ROIC |
0.00% | (6,622.08%) | (4,201.00%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(62.21%) | (77.81%) | (94.60%) | 417.60% | 262.59% | (130.03%) | (83.13%) | (316.36%) | (343.84%) |
Average Days of Receivables |
0.00 | 365.72 | 302.84 | 10,959.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 5,019.49% | 7,899.54% | 245,335.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 878.74% | 1,010.47% | 30,497.30% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.00 | 0.44 |
Share Based Compensation of Revenue |
0.00% | 77.17% | 148.45% | 5,872.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | 10.16 | 1.52 | (0.62) | — | — | — | — | — |
Graham Number |
— | 0.00 | 0.00 | 254.92 | — | — | — | — | — |
Earnings Yield |
— | (23.89%) | (1,338.04%) | (157.92%) | — | — | — | — | — |
Free Cash Flow Yield |
— | (1,692.84%) | (173.54%) | (125.36%) | — | — | — | — | — |
Revenue per Share |
0.00 | 44.17 | 1.49 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(7,061.25) | (2,661.22) | (130.26) | (84.60) | (34.05) | (1.45) | (1.51) | (3.03) | (1.36) |
Capex per Share |
0.00 | (70.61) | (0.15) | (0.02) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(7,061.25) | (2,731.83) | (130.42) | (84.62) | (34.05) | (1.46) | (1.51) | (3.04) | (1.36) |
Cash per Share |
15,505.63 | 3,410.09 | 145.18 | 4.99 | 9.10 | 7.47 | 4.97 | 1.85 | 1.22 |
Shareholders Equity per Share |
14,186.25 | 3,434.26 | 122.94 | (27.09) | (31.57) | 4.61 | 2.29 | (0.49) | (0.21) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14,186.25 | 3,434.26 | 122.94 | (27.09) | (31.57) | 4.61 | 2.29 | (0.49) | (0.21) |
Free Cash Flow |
(11.30) | (31.42) | (75.98) | (81.95) | (54.54) | (15.90) | (18.53) | (39.34) | (26.77) |
Working Capital |
21.64 | 37.05 | 80.75 | (25.27) | (20.23) | 70.33 | 53.38 | 12.08 | 7.18 |
Capital Expenditures |
— | (0.81) | (0.09) | (0.02) | (0.01) | (0.06) | (0.06) | (0.01) | 0.00 |
Net Current Asset Value |
21.64 | 36.97 | 66.72 | (40.27) | (61.88) | 41.99 | 23.61 | (7.07) | (23.89) |
EV/EBIT |
— | 0.00 | 0.35 | 0.00 | — | — | — | — | — |
Capex to Sales |
— | 1.60 | 0.10 | 0.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.09 | 0.71 | 0.90 | 26.34 | 68.14 | 59.97 | 80.18 | 111.83 |
Cash ROIC |
(23.78%) | (39.91%) | (44.62%) | 1,026.63% | 762.25% | (11.35%) | (18.74%) | (135.76%) | (66.36%) |
Accounts Receivable Turnover |
0.00 | 1.35 | 1.41 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 2.48 | 0.99 | 0.00 | 0.10 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 1,849.94 | 152.31 | 562.51 | 0.00 | 360.69 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Receivables |
0.38 | 0.38 | 0.62 | 0.92 | 0.99 | 1.04 | 0.75 | 0.17 | 0.04 |
Average Payables |
2.32 | 2.32 | 3.60 | 9.76 | 8.15 | 0.85 | 1.83 | 3.89 | 2.62 |
Average Assets |
36.84 | 36.84 | 72.31 | 61.81 | 29.27 | 62.15 | 79.17 | 46.55 | 35.43 |
Average Common Equity |
31.11 | 31.08 | 55.56 | 22.69 | (38.40) | (0.16) | 39.12 | 10.80 | (5.24) |
Columns are period end dates